Lisinopril and Losartan Interaction: Is It Safe?

Lisinopril (an ACE inhibitor) and losartan (an angiotensin receptor blocker, or ARB) are both widely prescribed blood pressure medications that work on the same hormone system — the renin-angiotensin-aldosterone system (RAAS). Using them together is called "dual RAAS blockade," and it is largely contraindicated based on evidence from large clinical trials. While the logic of combining them once seemed appealing, the evidence shows the combination offers no additional cardiovascular benefit over either drug alone, while significantly increasing the risk of dangerous low blood pressure, high potassium levels, and acute kidney injury.

What Happens When You Combine Them

The RAAS is a hormonal cascade that regulates blood pressure and fluid balance. Angiotensin II is a key molecule in this system — it causes blood vessels to constrict and the kidneys to retain sodium, both of which raise blood pressure. ACE inhibitors like lisinopril block the enzyme that converts angiotensin I to angiotensin II, reducing its production. ARBs like losartan block the receptor that angiotensin II acts on, preventing its effects even when it is present.

These drugs were designed to address the RAAS from different points, and early thinking held that combining them might produce superior blood pressure and kidney protection compared to either alone. However, the RAAS is also essential for maintaining adequate filtration pressure in the kidneys. When both drugs simultaneously suppress the system, the kidneys lose the ability to regulate their own blood flow, increasing the risk of acute kidney injury — particularly when patients are also dehydrated, ill, or taking NSAIDs or diuretics.

Additionally, both drug classes cause the kidneys to retain potassium by reducing aldosterone. When used in combination, potassium can accumulate to dangerously high levels (hyperkalemia) — a condition that can cause life-threatening heart rhythm abnormalities. Blood pressure can also fall severely, particularly when standing, causing fainting and falls.

Symptoms to Watch For

Monitor for the following if dual RAAS blockade is used:

• Hypotension: Dizziness, lightheadedness, or fainting when standing up; feeling of weakness or "passing out"
• Hyperkalemia: Muscle weakness, fatigue, tingling in limbs, irregular heartbeat or palpitations (often asymptomatic until severe)
• Acute kidney injury: Decreased urine output, swelling in legs/feet, unusual fatigue, elevated creatinine on blood tests
• Severe dehydration signs: Extreme thirst, dark urine, confusion — risk of AKI rises sharply with dehydration

Who Is Most at Risk

• Patients with pre-existing chronic kidney disease — already have impaired potassium excretion and reduced kidney reserve
• Elderly patients — more sensitive to blood pressure drops and potassium accumulation
• Patients also taking potassium-sparing diuretics or potassium supplements — further increases hyperkalemia risk
• Patients who become dehydrated — illness, hot weather, or reduced fluid intake dramatically increases AKI risk
• Patients also taking NSAIDs — NSAIDs impair kidney autoregulation and compound renal injury risk
• Diabetic patients with kidney disease — a population previously thought to benefit from dual blockade, but ONTARGET subgroup analysis did not support this

What to Do

If you are currently prescribed both: Do not stop either medication abruptly — both affect blood pressure regulation and sudden discontinuation can cause dangerous rebound hypertension. Schedule an urgent conversation with your prescriber to review whether the combination is appropriate and intentional.

If prescribed for a specific reason: There are rare, narrow clinical scenarios (such as certain proteinuric kidney diseases) where some experts have considered dual blockade under extremely close monitoring. This requires specialist supervision, frequent laboratory testing, and explicit acknowledgment of the risks. It is not appropriate as general blood pressure management.

Monitor for dehydration triggers: Illness, vomiting, diarrhea, or excessive heat exposure can rapidly worsen the risk of AKI for anyone on RAAS-blocking medications. Hold medications temporarily during acute illness only under your prescriber's guidance — do not make this decision independently.

Frequently Asked Questions